HBM Healthcare Investments AG / Key word (s): Quarter Results HBM Healthcare Investments reports a compelling 15 percent increase in NAV in the 2024 calendar year 03-Jan-2025 / 17:48 CET/CEST Release ...

The IPO is entirely an OFS, the company will not receive any funds from the issue and the proceeds will go to the selling ...

The biotech industry in 2024 was marked by some contradictions: Even as layoffs continued to rip through companies large and ...

Anthem Biosciences, a CRDMO specializing in drug discovery, development and manufacturing, has filed draft papers with Sebi ...

Indian contract drugmaker Anthem Biosciences filed for a 33.95-billion-rupee ($397 million) initial public offering, ...

Anthem, whose services include early-stage drug discovery and drug efficacy testing, said private equity firm True North and drugmaker DavosPharma are among investors who will sell shares in the IPO.

December has seen a flock of strong IPO debuts, including MobiKwik, Vishal Mega Mart, Inventurus Knowledge Solutions, and Sai ...

Mobikwik and Sai Life Sciences surge over 50% in IPO listings, while Vishal Megamart sees modest gains. Explore December's ...

The successful debuts are expected to boost the IPO market, with eight new issuances ... retailer Vishal Mega Mart and pharma firm Sai Life Sciences gained around 40 per cent each.